Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 32, Issue 12, Pages 686-693Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2011.08.004
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health (NIH) [HHSN261200800001E]
- European Commission [FP6-518230, TAMOP-4.2.2/B-10/1-2010-0013]
- Hungarian National Science Foundation (OTKA) [K69105, K83314]
- NIH National Cancer Institute, Center for Cancer Research
Ask authors/readers for more resources
Allosteric drugs are increasingly used because they produce fewer side effects. Allosteric signal propagation does not stop at the 'end' of a protein, but may be dynamically transmitted across the cell. We propose here that the concept of allosteric drugs can be broadened to 'allo-network drugs' - whose effects can propagate either within a protein, or across several proteins, to enhance or inhibit specific interactions along a pathway. We posit that current allosteric drugs are a special case of allo-network drugs, and suggest that allo-network drugs can achieve specific, limited changes at the systems level, and in this way can achieve fewer side effects and lower toxicity. Finally, we propose steps and methods to identify allo-network drug targets and sites that outline a new paradigm in systems-based drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available